Evaluation of DR-2001 for the Management of Endometriosis-Related Pelvic Pain - Full Text View

Purpose

This is a 3-arm, multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy of DR-2001 in endometriosis-related symptoms, primarily nonmenstrual pelvic pain, over a 12-week treatment period.

Condition	Intervention	Phase
Endometriosis	Drug: DR-2001a Drug: DR-2001b Other: Placebo	Phase 2


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Participant, Investigator) Primary Purpose: Treatment
Official Title:	A Phase 2, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate DR-2001 for the Management of Moderate to Severe Endometriosis-Related Nonmenstrual Pelvic Pain

Resource links provided by NLM:

MedlinePlus related topics: Endometriosis Pelvic Pain

U.S. FDA Resources

Further study details as provided by Teva Pharmaceutical Industries:

Primary Outcome Measures:

Mean change in nonmenstrual pelvic pain at end of treatment [ Time Frame: Baseline to Week 12/Early Withdrawal Visit ]

Secondary Outcome Measures:

Mean change in nonmenstrual pelvic pain and endometriosis-related symptoms [ Time Frame: Weeks 4, 8 and 12 ]
Safety and tolerability of DR-2001 [ Time Frame: Throughout study period ]


Estimated Enrollment:	90
Study Start Date:	June 2005
Study Completion Date:	December 2007
Primary Completion Date:	December 2007 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: 1	Drug: DR-2001a DR-2001a administered vaginally each month
Experimental: 2	Drug: DR-2001b DR-2001b administered vaginally each month
Placebo Comparator: 3	Other: Placebo Placebo administered vaginally each month

Detailed Description:

This multicenter, double-blind, randomized, placebo-controlled study is designed to evaluate the ability of DR-2001 to produce beneficial changes in endometriosis-related symptoms, primarily nonmenstrual pelvic pain, over a 12-week treatment period. The overall study duration for each patient will be about 20 weeks.

Patients who meet all study entrance criteria will be randomly assigned to one of three treatment groups.

The change in endometriosis-related clinical symptoms will be assessed in two ways: through a combined physician/patient assessment and also with a patient self-assessment. Patients will undergo a gynecologic exam at each study visit.

Eligibility


Ages Eligible for Study:	18 Years to 45 Years (Adult)
Sexes Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Surgically sterilized (patient or partner), willing to use condoms throughout the study, or otherwise not at risk for pregnancy
Diagnosis of endometriosis within the last 5 years
Moderate or severe nonmenstrual pelvic pain
Premenopausal
Not pregnant or breastfeeding
Regular (24-35 day) menstrual cycles for at least 2 months

Exclusion Criteria:

Undiagnosed abnormal genital bleeding
Any contraindication to the use of hormonal therapy
Prior surgery for endometriosis
GnRH analog therapy within 5 months
Use of estrogens and/or progestins within 2 months
Pain symptoms unrelated to endometriosis
Any contraindication to the use of vaginal delivery systems

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00117481

Show 41 Study Locations

Sponsors and Collaborators

Duramed Research

Investigators


Study Chair:	Duramed Protocol Chair	Duramed Research, Inc.

More Information


Responsible Party:	Duramed Protocol Chair, Duramed Research, Inc.
ClinicalTrials.gov Identifier:	NCT00117481 History of Changes
Other Study ID Numbers:	DR-DZL-201
Study First Received:	June 30, 2005
Last Updated:	May 8, 2014

Keywords provided by Teva Pharmaceutical Industries:


endometriosis pelvic pain hormonal treatment

Additional relevant MeSH terms:


Endometriosis Pelvic Pain Genital Diseases, Female	Pain Neurologic Manifestations Signs and Symptoms

ClinicalTrials.gov processed this record on June 22, 2017